Glucagon-like Peptide 1 Market Set for Strong Growth: From $20.88 Billion in 2024 to $31.27 Billion By 2029 CAGR 8.7%

The glucagon-like peptide 1 market size has been growing robustly in recent years. From $20.88 billion in 2024, it will reach $22.37 billion in 2025, evolving at a compound annual growth rate (CAGR) of 7.1%. This growth can be attributed to the rising prevalence of diabetes, improved diabetes management, patients’ preference for injectable therapies, advancements in diabetes research, superb clinical efficacy, and safety profiles.

The market is slated to experience strong growth in the coming years, soaring to $31.27 billion in 2029 at a CAGR of 8.7%. The growth pattern in the forecast period will be driven by the emergence of oral GLP-1 therapies, focus on personalized medicine, integration in diabetes treatment algorithms, and patient-centric approaches in healthcare. Other trends influencing the market include market expansion in emerging economies, regulatory approvals for new formulations, focus on personalized medicine, patient education, and awareness programs, and dynamic competitive landscape.

See a sample of the Glucagon-like Peptide 1 Market Report here: https://www.thebusinessresearchcompany.com/sample.aspx?id=10830&type=smp

What Are The Key Drivers Of Glucagon-like Peptide 1 Market Growth?
The rising prevalence of diabetes is expected to ignite the growth engine for the global glucagon-like peptide 1 market. Elevating levels of blood sugar or blood glucose define diabetes, a condition for which Glucagon-like peptide 1 serves as a credible medication, addressing type 2 diabetes and potentially aiding weight loss. A January 2022 report from the National Library of Medicine states that the global diabetes prevalence among 20-79-year-olds was 10.5% (536.6 million people) in 2021, projecting an increase to 12.2% (783.2 million) by 2045. Therefore, the rising prevalence of diabetes is poised to drive the glucagon-like peptide 1 market.

What Are The Key Segments For The Global Glucagon-like Peptide 1 Market?
The glucagon-like peptide 1 market detailed in this report is segmented as follows:
– By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
– By Route of Administration: Oral, Parenteral, Other Routes
– By End-Users: Hospitals, Specialty Clinics, Other End Users

To purchase the complete report, visit: https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

Who Are The Major Players In The Glucagon-like Peptide 1 Market?
Major companies operating in the glucagon-like peptide 1 market include Novo Nordisk AS, Sanofi SA, Eli Lilly and Co, AstraZeneca plc, Pfizer Inc, Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Baxter, Hikma Pharmaceuticals plc, Zealand Pharma A/S, Intarcia Therapeutics Inc., GlaxoSmithKline plc, Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Benemae Pharmaceutical Corporation, Adocia, Biocon, Hanmi Pharmaceutical Co Ltd, Ligand Pharmaceuticals Incorporated, Advinus Therapeutics Ltd, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Union Chimique Belge, Amylin Pharmaceuticals LLC, Academic Pharmaceuticals Inc, ConjuChem Biotechnologies, MannKind Corporation:, Provention Bio Inc, Regeneron Pharmaceuticals.

What Trends Are Emerging In The Glucagon-like Peptide 1 Market?
Technological innovations are defining the future trajectory of the global glucagon-like peptide 1 market. For maintaining their market position and competitive edge, companies are launching innovative technologies. A case in point is Wegovy, the world’s first once-weekly glucagon-like peptide 1 therapy for weight management, released by Denmark-based pharmaceutical company Novo Nordisk A/S in March 2024. Wegovy cleared the STEP Phase 3a clinical trial program and showed a safe and well-tolerated profile. Its primary use is to combat obesity and maintain weight loss.

What Are The Largest and Fastest-Growing Regions For The Glucagon-like Peptide 1 Market?
North America dominated the glucagon-like peptide 1 market in 2024. The regions covered by the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

What Does The Glucagon-like Peptide 1 Market Report 2025 Offer?
Glucagon-like peptide 1 refers to a kind of amino acid hormone of peptide produced in the L-cells of the intestinal epithelial endocrine. This hormone has been successfully used to treat diseases and conditions such as diabetes and obesity. The Glucagon-like Peptide 1 Market research report from The Business Research Company provides global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Exclusive report available for purchase at: https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10830

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Leave a Reply

Your email address will not be published. Required fields are marked *